These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks? Heart Advis; 2009 Aug; 12(8):8. PubMed ID: 21188763 [No Abstract] [Full Text] [Related]
4. Dopamine agonists and the risk of cardiac-valve regurgitation. Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453 [TBL] [Abstract][Full Text] [Related]
5. Pergolide in Parkinson's disease: time for a change? Grosset KA; Grosset DG Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636 [No Abstract] [Full Text] [Related]
6. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648 [TBL] [Abstract][Full Text] [Related]
7. Mitral heart disease due to cabergoline. Martin M; Iglesias-Cubero G; Diaz Molina B; Moris De la Tassa C Int J Cardiol; 2007 Jan; 114(1):e7-8. PubMed ID: 17052783 [TBL] [Abstract][Full Text] [Related]
8. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289 [TBL] [Abstract][Full Text] [Related]
9. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285 [TBL] [Abstract][Full Text] [Related]